Skip to main content
    S

    Sonoma Pharmaceuticals Inc (SNOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.88
    -0.21 (-19.25%)

    Market Cap: $5.52M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Sonoma Pharmaceuticals Inc (SNOA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Sonoma Pharmaceuticals (SNOA) trades at 0.2x sales and 0.7x book value. Its P/S of 0.2x is below its 5-year median of 0.3x. Its forward P/E is 46.1x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E46.1x
    Price to sales0.2x
    Price to book0.7x
    PEGN/A
    FCF yield-64.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 46.2% below 1.3x.

    MultipleCurrent5-year median10-year median
    P/S0.2x0.3xN/A
    P/B0.7x1.2x1.3x
    Medians of month-end values through Oct 2026: 50 to 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 0.2x in 2024 to 17.1x in 2021.

    Year endPriceP/EP/SP/B
    2025$3.64N/A0.3x1.8x
    2024$2.69N/A0.2x0.8x
    2023$3.61N/AN/A0.3x
    2022$22.40N/A6.0x18.7x
    2021$91.20N/A17.1x25.1x
    2020$145.20N/AN/A24.2x
    2019$87.20N/A0.4x0.6x
    2018$128.26N/AN/A0.5x
    2017$981.10N/AN/A1.7x
    2016$907.291.6xN/A0.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About SNOA

    What is SNOA's forward P/E ratio?

    Sonoma Pharmaceuticals has a forward P/E ratio of 46.1x.

    What is SNOA's price to sales ratio?

    Sonoma Pharmaceuticals has a price to sales ratio of 0.2x.